Breaking News

Eisai Enters License Agreement with Roivant

Grants the exclusive rights for global research, development, manufacture and sale of H3B-8800 to a subsidiary of Roivant Sciences Ltd.

Author Image

By: Charlie Sternberg

Associate Editor

Eisai Co., Ltd. has entered into a License Agreement granting the exclusive rights for global research, development, manufacture and sale of the investigational anticancer agent H3B-8800 to a subsidiary of Roivant Sciences Ltd. H3B-8800 is an orally available small molecule modulator of splicing factor 3B subunit 1 (SF3B1), discovered by H3 Biomedicine Inc. Splicing occurs to remove introns that are base sequence of pre-messenger RNA (mRNA), unneeded for protein synthesis, in the process of syn...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters